Ipsen SA is set to bid adieu to its over-the-counter activities and concentrate on specialty pharma after announcing that it is in talks to sell its consumer healthcare business to fellow French group Mayoly-Spindler SAS.
The switch in strategy, which was revealed as Ipsen posted a reasonable set of fourth quarter results, involves "exclusive negotiations"...








